Pivot Pharmaceuticals attains prestigious CSE25 status Recent acquisitions have extended the company’s portfolio in the cannabis space Numerous pharmaceutical and nutraceutical products in development pipeline Canadian biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF)…
Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it has successfully completed the integration of its California subsidiary, ERS Holdings Ltd., under the guidance of Patrick Rolfes,…
Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) this morning announced that, effective March 16, 2018, the company has been named to the CSE25 Index, a composite of the 25 largest companies, as…
Owns worldwide rights for patented formulations and drug delivery technologies Develops and commercializes therapeutic pharmaceuticals and nutraceuticals Strategic agenda to become one of world’s only vertically integrated cannabis biotechs With worldwide rights for unique drug…
Pivot Pharmaceuticals developing disruptive formulations for cannabis-infused markets Company’s goal is to strengthen dosage predictability and improve product stability Recent acquisitions and planned acquisitions give Pivot vertical position in multi-billion-dollar industries Despite recent setbacks to…
Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) this morning announced that it has retained Cannabis Compliance Inc. (“CCI”) in order to submit an application, on behalf of Agro-Biotech Inc., to Health Canada…
Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) this morning announced its acquisition of Thrudermic, LLC, a privately-held North Carolina company. Per the update, Pivot will pay $1.00 for all of the listed…
Pivot Pharmaceuticals (CSE: PVOT) (OTCQB: PVOTF) this morning announced the closing of its private placement of convertible debentures for gross proceeds totaling C$5 million. The company issued a total of C$5 million of 10% senior…
Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) this morning announced the successful completion of its acquisition of ERS Holdings, LLC (“ERS”). ERS, a privately-held California company, has developed a patented technology called Ready-To-Infuse-Cannabis (“RTIC”) which…
Forecasts envision medical cannabis market reaching $55.8 billion by 2025 PVOTF filing patents for smoked, transdermal and mucosal delivery of therapeutics Global partnerships and acquisitions open windows of opportunity for company With its recently announced…
Letter of Intent to acquire Agro-Biotech, to become vertically integrated from “seed to derivatives” Development and commercialization of therapeutic pharmaceuticals and nutraceuticals Patented formulation and delivery technologies Scientific studies have provided empirical credence to the…
Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) yesterday announced its entry into a non-binding letter of intent pursuant to which it proposes to acquire Agro-Biotech Inc., a Health Canada ACMPR licensed producer…
Update highlights proposed acquisitions, product development and growing IP portfolio Three new patent filings join established global rights to other patented technologies Innovative transdermal delivery technology increases bioavailability of cannabinoids Global cannabis market projected to…
Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) this morning issued a corporate update detailing its recent activity. Per the release, the company has had a “very active” start to the current calendar year, with…
Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) is focused on providing the health care marketplace with nutraceutical and pharmaceutical options for treating certain unmet needs. That extends to the medical cannabis industry, where the lack of a…